GEHC's price trend over the past year has been characterized by a significant decline followed by a recent recovery, with the stock currently trading at $74.82, up 2.28% from a year ago but down 9.66% year-to-date. The stock sits at 83.3% of its 52-week range (between $58.75 low and $89.77 high), indicating a recovery from the lows but still below the highs. This positioning suggests the stock is in a recovery phase, with potential for further upside if momentum continues, though it remains below its previous peak, reflecting lingering bearish sentiment from the earlier downtrend.

GEHC's revenue trajectory shows moderate growth, with the most recent quarter (Q1 2026) reporting revenue of $5.131 billion, up 7.41% year-over-year. This growth is driven by strong performance in the Imaging segment ($2.299 billion) and Pharmaceutical Diagnostics ($770 million), while Patient Care Solutions contributed $704 million. However, the growth rate has decelerated from the 8.4% YoY growth seen in Q4 2025, indicating a slight slowdown. The company's profitability remains solid, with a net income of $389 million in Q1 2026, translating to a net margin of 7.58%, which is lower than the 13.5% margin in Q4 2024 but consistent with recent quarters. Gross margin stood at 38.53% in Q1 2026, down from 54.3% in Q4 2025, reflecting cost pressures and product mix shifts. The balance sheet shows a debt-to-equity ratio of 0.96, indicating moderate leverage, and a current ratio of 1.18, suggesting adequate liquidity. Free cash flow for the trailing twelve months was $1.52 billion, with Q1 2026 generating $112 million, down from $917 million in Q4 2025, reflecting seasonal working capital swings. The company's ROE is 20.08%, indicating strong returns on equity, and it maintains a dividend yield of 0.17% with a payout ratio of 3.07%, leaving ample room for reinvestment.